The neuroprotection in PD models involving modulation of MEF2D activity was also revealed for the following: chrysin [92]; T-006, a novel tetramethylpyrazine derivative [80]; salidroside [93]; the anti-cancer drug SU4312 [15]; a modified p5 peptide, TFP5 [94]; and danshensu, an active ingredient of Salvia miltiorrhiza [95]. This evidence concerns the gene MEF2D and Parkinson disease.